Literature DB >> 21249485

Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in breast cancer patients.

Lidija Beketic-Oreskovic1, Petar Ozretic, Zahid N Rabbani, Isabel L Jackson, Bozena Sarcevic, Sonja Levanat, Petra Maric, Ivan Babic, Zeljko Vujaskovic.   

Abstract

The aim of this study was to examine the prognostic significance of carbonic anhydrase IX (CA-IX), an endogenous marker for tumor hypoxia; endoglin (CD105), a proliferation-associated and hypoxia-inducible glycoprotein and 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidative DNA lesion, in breast cancer patients. Immunohistochemical expressions of CA-IX, CD105 and 8-OHdG, analyzed on paraffin-embedded tumor tissues from forty female breast cancer patients, were used to assess their prognostic implication on overall survival (OS) and relapse-free survival (RFS). Patients with high CA-IX expression (above cut-off value) had a higher occurrence of relapse (P = = 0.002). High CA-IX expression was significantly associated with shorter RFS (P < 0.001, hazard ratio (HR) 0.21) and shorter OS (P < 0.001, HR 0.19). Lymph node negative patients with high CA-IX expression had worse RFS (P = 0.031, HR 0.14) and OS (P = 0.005, HR 0.05). Patients with grade I&II tumors and high CA-IX expression showed shorter RFS (P = 0.028, HR 0.28) and OS (P = 0.008, HR 0.20). Worse OS (P = 0.046, HR 0.28) was found in subgroup of patients with grade II tumors and high CA-IX expression. Among all three markers, only high CA-IX expression was strong independent prognostic indicator for shorter OS (HR 4.14, 95% CI 1.28-13.35, P = 0.018) and shorter RFS (HR 3.99, 95% CI 1.38-11.59, P = 0.011). Elevated expression of CA-IX was an independent prognostic factor for decreased RFS and OS and a significant marker for tumor aggressiveness. CD105 had week prognostic value; whereas, 8-OHdG, in this study, did not provide sufficient evidence as a prognostic indicator in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21249485     DOI: 10.1007/s12253-010-9355-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  50 in total

1.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors:  C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

2.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.

Authors:  P R Rosen; S Groshen; P E Saigo; D W Kinne; S Hellman
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

3.  Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma.

Authors:  J M McKiernan; R Buttyan; N H Bander; M D Stifelman; A E Katz; M W Chen; C A Olsson; I S Sawczuk
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

4.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.

Authors:  S K Chia; C C Wykoff; P H Watson; C Han; R D Leek; J Pastorek; K C Gatter; P Ratcliffe; A L Harris
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

Review 5.  Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

Authors:  P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

6.  Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.

Authors:  M M Vleugel; A E Greijer; A Shvarts; P van der Groep; M van Berkel; Y Aarbodem; H van Tinteren; A L Harris; P J van Diest; E van der Wall
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

7.  DNA oxidation and antioxidant status in breast cancer.

Authors:  Solen Himmetoglu; Yldz Dincer; Yeliz E Ersoy; Barş Bayraktar; Varol Celik; Tulay Akcay
Journal:  J Investig Med       Date:  2009-08       Impact factor: 2.895

Review 8.  Mitochondrial complex III regulates hypoxic activation of HIF.

Authors:  T Klimova; N S Chandel
Journal:  Cell Death Differ       Date:  2008-01-25       Impact factor: 15.828

Review 9.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.

Authors:  R M Elledge; W L McGuire
Journal:  Annu Rev Med       Date:  1993       Impact factor: 13.739

10.  Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption.

Authors:  M B Parliament; A J Franko; M J Allalunis-Turner; B W Mielke; C L Santos; B G Wolokoff; J R Mercer
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  11 in total

1.  Interaction-based feature selection and classification for high-dimensional biological data.

Authors:  Haitian Wang; Shaw-Hwa Lo; Tian Zheng; Inchi Hu
Journal:  Bioinformatics       Date:  2012-09-03       Impact factor: 6.937

2.  Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma.

Authors:  Jia-Sin Yang; Chiao-Wen Lin; Chun-Yi Chuang; Shih-Chi Su; Shu-Hui Lin; Shun-Fa Yang
Journal:  Tumour Biol       Date:  2015-07-01

3.  Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma.

Authors:  Fion L Sung; Yan Cui; Edwin P Hui; Lili Li; Thomas Ks Loh; Qian Tao; Anthony Tc Chan
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

4.  CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells.

Authors:  Samantha Ames; Jacob T Andring; Robert McKenna; Holger M Becker
Journal:  Oncogene       Date:  2019-11-13       Impact factor: 9.867

5.  Proton export upregulates aerobic glycolysis.

Authors:  Shonagh Russell; Liping Xu; Yoonseok Kam; Dominique Abrahams; Bryce Ordway; Alex S Lopez; Marilyn M Bui; Joseph Johnson; Tamir Epstein; Epifanio Ruiz; Mark C Lloyd; Pawel Swietach; Daniel Verduzco; Jonathan Wojtkowiak; Robert J Gillies
Journal:  BMC Biol       Date:  2022-07-15       Impact factor: 7.364

Review 6.  The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.

Authors:  Arthur Adams; Aram S A van Brussel; Jeroen F Vermeulen; Willem P Th M Mali; Elsken van der Wall; Paul J van Diest; Sjoerd G Elias
Journal:  BMC Cancer       Date:  2013-11-10       Impact factor: 4.430

7.  The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.

Authors:  An Wouters; Bea Pauwels; Natalie Burrows; Marc Baay; Vanessa Deschoolmeester; Trung Nghia Vu; Kris Laukens; Paul Meijnders; Dirk Van Gestel; Kaye J Williams; Danielle Van den Weyngaert; Jan B Vermorken; Patrick Pauwels; Marc Peeters; Filip Lardon
Journal:  BMC Cancer       Date:  2014-08-16       Impact factor: 4.430

8.  Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model.

Authors:  Hong Zhang; Hongxiu Diao; Lixin Jia; Yujing Yuan; Douglas H Thamm; Huanan Wang; Yipeng Jin; Shimin Pei; Bin Zhou; Fang Yu; Linna Zhao; Nan Cheng; Hongchao Du; Ying Huang; Di Zhang; Degui Lin
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

Review 9.  Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis.

Authors:  Simon J A van Kuijk; Ala Yaromina; Ruud Houben; Raymon Niemans; Philippe Lambin; Ludwig J Dubois
Journal:  Front Oncol       Date:  2016-03-29       Impact factor: 6.244

10.  Prognostic value of endoglin-assessed microvessel density in cancer patients: a systematic review and meta-analysis.

Authors:  Jinguo Zhang; Lingyun Zhang; Qunbo Lin; Weimin Ren; Guoxiong Xu
Journal:  Oncotarget       Date:  2017-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.